RegenMedTX Overview

  • Founded
  • 2014

Founded
  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

RegenMedTX General Information

Description

Developer of cell therapies for chronic kidney disease. The company develops cell therapy products that are programmed in the body to restore damaged kidney tissues by engrafting into, repairing or replacing damaged tissues or organ.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly Angel backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 3929 Westpoint Boulevard
  • Suite G
  • Winston-Salem, NC 27103
  • United States
+1 (336) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

RegenMedTX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 01-Mar-2016 00.000 Completed Startup
1. Seed Round 05-Aug-2015 00.000 00.000 Completed Startup
To view RegenMedTX’s complete valuation and funding history, request access »

RegenMedTX Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of cell therapies for chronic kidney disease. The company develops cell therapy products that are programmed i
Biotechnology
Winston-Salem, NC
00.000
000000&0 00.000

000000

cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in cul
0000 000000000
Ann Arbor, MI
00 As of 0000
00000
000000 - 000 00000

000000

empor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitatio
0000 000000000
Oslo, Norway
00 As of 0000
00000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

RegenMedTX Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lycera Venture Capital-Backed Ann Arbor, MI 00 00000 000000 - 000 00000
0000000 Venture Capital-Backed Oslo, Norway 00 00000000000
0000000 Formerly VC-backed Waltham, MA 000 00000 000000 - 000 00000
You’re viewing 3 of 3 competitors. Get the full list »

RegenMedTX Patents

RegenMedTX Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20160101133-A1 Organoids comprising isolated renal cells and use thereof Pending 08-May-2013 000000000 00
CA-2911291-A1 Organoids comprising isolated renal cells and uses thereof Pending 08-May-2013 000000000
AU-2014262670-A1 Organoids comprising isolated renal cells and uses thereof Granted 08-May-2013 000000000
AU-2014262670-B2 Organoids comprising isolated renal cells and uses thereof Active 08-May-2013 0000000000 0
AU-2020203860-A1 Organoids comprising isolated renal cells and uses thereof Pending 08-May-2013 C12N5/0697
To view RegenMedTX’s complete patent history, request access »

RegenMedTX Executive Team (2)

Name Title Board Seat Contact Info
Deepak Jain Ph.D Chief Operating Officer
You’re viewing 1 of 2 executive team members. Get the full list »

RegenMedTX Board Members (3)

Name Representing Role Since
Kim Westmoreland Self Board Member 000 0000
William Hawkins III Self Chairman 000 0000
You’re viewing 2 of 3 board members. Get the full list »

RegenMedTX Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 01-Nov-2017 000000000 Biotechnology
Tengion 06-Mar-2015 Merger/Acquisition 000.00 Biotechnology
To view RegenMedTX’s complete investments and acquisitions history, request access »